Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2011

Open Access 01-12-2011 | Research article

Caveolin 1 protein expression in renal cell carcinoma predicts survival

Authors: Sandra Steffens, Andres J Schrader, Hanna Blasig, Gesa Vetter, Hendrik Eggers, Wolfgang Tränkenschuh, Markus A Kuczyk, Jürgen Serth

Published in: BMC Urology | Issue 1/2011

Login to get access

Abstract

Background

Caveolae play a significant role in disease phenotypes such as cancer, diabetes, bladder dysfunction, and muscular dystrophy. The aim of this study was to elucidate the caveolin-1 ( CAV1) protein expression in renal cell cancer (RCC) and to determine its potential prognostic relevance.

Methods

289 clear cell RCC tissue specimens were collected from patients undergoing surgery for renal tumors. Both cytoplasmic and membranous CAV1 expression were determined by immunohistochemistry and correlated with clinical variables. Survival analysis was carried out for 169 evaluable patients with a median follow up of 80.5 months (interquartile range (IQR), 24.5 - 131.7 months).

Results

A high CAV1 expression in the tumor cell cytoplasm was significantly associated with male sex (p = 0.04), a positive nodal status (p = 0.04), and poor tumor differentiation (p = 0.04). In contrast, a higher than average (i.e. > median) CAV1 expression in tumor cell membranes was only linked to male sex (p = 0.03). Kaplan-Meier analysis disclosed significant differences in 5-year overall (51.4 vs. 75.2%, p = 0.001) and tumor specific survival (55.3 vs. 80.1%, p = 0.001) for patients with higher and lower than average cytoplasmic CAV1 expression levels, respectively. Applying multivariable Cox regression analysis a high CAV1 protein expression level in the tumor cell cytoplasm could be identified as an independent poor prognostic marker of both overall (p = 0.02) and tumor specific survival (p = 0.03) in clear cell RCC patients.

Conclusion

Over expression of caveolin-1 in the tumour cell cytoplasm predicts a poor prognosis of patients with clear cell RCC. CAV1 is likely to be a useful prognostic marker and may play an important role in tumour progression. Therefore, our data encourage further investigations to enlighten the role of CAV1 and its function as diagnostic and prognostic marker in serum and/or urine of RCC patients.
Appendix
Available only for authorised users
Literature
1.
Schrader AJ, Sevinc S, Olbert PJ, Hegele A, Varga Z, Hofmann R: [Gender-specific characteristics and survival of renal cell carcinoma]. Der Urologe Ausg. 2008, 47 (9): 1182, 1184-1186.
2.
Tamaskar I, Choueiri TK, Sercia L, Rini B, Bukowski R, Zhou M: Differential expression of caveolin-1 in renal neoplasms. Cancer. 2007, 110 (4): 776-782.CrossRefPubMed
3.
Engelman JA, Wykoff CC, Yasuhara S, Song KS, Okamoto T, Lisanti MP: Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. The Journal of biological chemistry. 1997, 272 (26): 16374-16381.CrossRefPubMed
4.
Engelman JA, Zhang XL, Galbiati F, Lisanti MP: Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav-1, -2, and -3). Cav-1 and Cav-2 genes map to a known tumor suppressor locus (6-A2/7q31). FEBS letters. 1998, 429 (3): 330-336.CrossRefPubMed
5.
Engelman JA, Zhang XL, Lisanti MP: Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS letters. 1998, 436 (3): 403-410.CrossRefPubMed
6.
Engelman JA, Zhang XL, Lisanti MP: Sequence and detailed organization of the human caveolin-1 and -2 genes located near the D7S522 locus (7q31.1). Methylation of a CpG island in the 5' promoter region of the caveolin-1 gene in human breast cancer cell lines. FEBS letters. 1999, 448 (2-3): 221-230.CrossRefPubMed
7.
Furuchi T, Anderson RG: Cholesterol depletion of caveolae causes hyperactivation of extracellular signal-related kinase (ERK). The Journal of biological chemistry. 1998, 273 (33): 21099-21104.CrossRefPubMed
8.
Galbiati F, Volonte D, Engelman JA, Watanabe G, Burk R, Pestell RG, Lisanti MP: Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. The EMBO journal. 1998, 17 (22): 6633-6648.CrossRefPubMedPubMedCentral
9.
Koleske AJ, Baltimore D, Lisanti MP: Reduction of caveolin and caveolae in oncogenically transformed cells. Proceedings of the National Academy of Sciences of the United States of America. 1995, 92 (5): 1381-1385.CrossRefPubMedPubMedCentral
10.
Lee SW, Reimer CL, Oh P, Campbell DB, Schnitzer JE: Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene. 1998, 16 (11): 1391-1397.CrossRefPubMed
11.
Sager R, Sheng S, Anisowicz A, Sotiropoulou G, Zou Z, Stenman G, Swisshelm K, Chen Z, Hendrix MJ, Pemberton P, et al: RNA genetics of breast cancer: maspin as paradigm. Cold Spring Harbor symposia on quantitative biology. 1994, 59: 537-546.CrossRefPubMed
12.
Scherer PE, Okamoto T, Chun M, Nishimoto I, Lodish HF, Lisanti MP: Identification, sequence, and expression of caveolin-2 defines a caveolin gene family. Proceedings of the National Academy of Sciences of the United States of America. 1996, 93 (1): 131-135.CrossRefPubMedPubMedCentral
13.
Campbell L, Gumbleton M, Griffiths DF: Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. British journal of cancer. 2003, 89 (10): 1909-1913.CrossRefPubMedPubMedCentral
14.
Mengel M, Kreipe H, von Wasielewski R: Rapid and large-scale transition of new tumor biomarkers to clinical biopsy material by innovative tissue microarray systems. Appl Immunohistochem Mol Morphol. 2003, 11 (3): 261-268.CrossRefPubMed
15.
Guinan P, Sobin LH, Algaba F, Badellino F, Kameyama S, MacLennan G, Novick A: TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997, 80 (5): 992-993.CrossRefPubMed
16.
Fuhrman SA, Lasky LC, Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. The American journal of surgical pathology. 1982, 6 (7): 655-663.CrossRefPubMed
17.
Stenzl A, deKernion JB: Pathology, biology, and clinical staging of renal cell carcinoma. Seminars in oncology. 1989, 16 (1 Suppl 1): 3-11.PubMed
18.
Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF: Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer. 1997, 80 (11): 2109-2119.CrossRefPubMed
19.
Merseburger AS, Hennenlotter J, Simon P, Muller CC, Kuhs U, Knuchel-Clarke R, Moul JW, Stenzl A, Kuczyk MA: Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions. Oncol Rep. 2006, 16 (1): 79-83.PubMed
20.
Merseburger AS, Kramer MW, Hennenlotter J, Simon P, Knapp J, Hartmann JT, Stenzl A, Serth J, Kuczyk MA: Involvement of decreased Galectin-3 expression in the pathogenesis and progression of prostate cancer. The Prostate. 2008, 68 (1): 72-77.CrossRefPubMed
21.
Tezval H, Jurk S, Atschekzei F, Serth J, Kuczyk MA, Merseburger AS: The involvement of altered corticotropin releasing factor receptor 2 expression in prostate cancer due to alteration of anti-angiogenic signaling pathways. The Prostate. 2008
22.
Peters I, Rehmet K, Wilke N, Kuczyk MA, Hennenlotter J, Eilers T, Machtens S, Jonas U, Serth J: RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis. Molecular cancer. 2007, 6: 49-CrossRefPubMedPubMedCentral
23.
Yang G, Truong LD, Wheeler TM, Thompson TC: Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer research. 1999, 59 (22): 5719-5723.PubMed
24.
Bender FC, Reymond MA, Bron C, Quest AF: Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer research. 2000, 60 (20): 5870-5878.PubMed
25.
Racine C, Belanger M, Hirabayashi H, Boucher M, Chakir J, Couet J: Reduction of caveolin 1 gene expression in lung carcinoma cell lines. Biochemical and biophysical research communications. 1999, 255 (3): 580-586.CrossRefPubMed
26.
Wiechen K, Diatchenko L, Agoulnik A, Scharff KM, Schober H, Arlt K, Zhumabayeva B, Siebert PD, Dietel M, Schafer R, et al: Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. The American journal of pathology. 2001, 159 (5): 1635-1643.CrossRefPubMedPubMedCentral
27.
Wiechen K, Sers C, Agoulnik A, Arlt K, Dietel M, Schlag PM, Schneider U: Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. The American journal of pathology. 2001, 158 (3): 833-839.CrossRefPubMedPubMedCentral
28.
Horiguchi A, Asano T, Asakuma J, Asano T, Sumitomo M, Hayakawa M: Impact of caveolin-1 expression on clinicopathological parameters in renal cell carcinoma. The Journal of urology. 2004, 172 (2): 718-722.CrossRefPubMed
29.
Waalkes S, Eggers H, Blasig H, Atschekzei F, Kramer MW, Hennenlotter J, Trankenschuh W, Stenzl A, Serth J, Schrader AJ: Caveolin 1 mRNA is overexpressed in malignant renal tissue and might serve as a novel diagnostic marker for renal cancer. Biomarkers in medicine. 5 (2): 219-225.
30.
Mete O, Kilicaslan I, Gulluoglu MG, Uysal V: Can renal oncocytoma be differentiated from its renal mimics? The utility of anti-mitochondrial, caveolin 1, CD63 and cytokeratin 14 antibodies in the differential diagnosis. Virchows Arch. 2005, 447 (6): 938-946.CrossRefPubMed
31.
Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L, Goltsov A, Ittmann M, Morrisett JD, Thompson TC: Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer research. 2001, 61 (10): 3882-3885.PubMed
32.
Tahir SA, Frolov A, Hayes TG, Mims MP, Miles BJ, Lerner SP, Wheeler TM, Ayala G, Thompson TC, Kadmon D: Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res. 2006, 12 (16): 4872-4875.CrossRefPubMed
33.
Puyraimond A, Fridman R, Lemesle M, Arbeille B, Menashi S: MMP-2 colocalizes with caveolae on the surface of endothelial cells. Experimental cell research. 2001, 262 (1): 28-36.CrossRefPubMed
34.
Loeb LA, Loeb KR, Anderson JP: Multiple mutations and cancer. Proceedings of the National Academy of Sciences of the United States of America. 2003, 100 (3): 776-781.CrossRefPubMedPubMedCentral
35.
Campbell L, Jasani B, Edwards K, Gumbleton M, Griffiths DF: Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma. British journal of cancer. 2008, 98 (5): 931-940.CrossRefPubMedPubMedCentral
36.
Kondagunta GV, Drucker B, Schwartz L, Bacik J, Marion S, Russo P, Mazumdar M, Motzer RJ: Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol. 2004, 22 (18): 3720-3725.CrossRefPubMed
Metadata
Title
Caveolin 1 protein expression in renal cell carcinoma predicts survival
Authors
Sandra Steffens
Andres J Schrader
Hanna Blasig
Gesa Vetter
Hendrik Eggers
Wolfgang Tränkenschuh
Markus A Kuczyk
Jürgen Serth
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2011
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/1471-2490-11-25

Other articles of this Issue 1/2011

BMC Urology 1/2011 Go to the issue

Research article

Urethral catheters: can we reduce use?

Research article

Clinical significance of subepithelial growth patterns in non-muscle invasive bladder cancer

Research article

The primary therapy chosen for patients with localized prostate cancer between the university hospital and its affiliated hospitals in Nara Uro-oncological research group registration

Research article

Immunocytochemical characterisation of cultures of human bladder mucosal cells

Case report

Hemangioma of the prostate - an unusual cause of lower urinary tract symptoms: Case report

Research article

ROS generation via NOX4 and its utility in the cytological diagnosis of urothelial carcinoma of the urinary bladder